Can Employee Releases Bar False Claims Act Actions?
Client Alert | 1 min read | 03.15.06
Government contractors should take notice that recent court decisions indicate a possible shift in the law that may foretell greater success in using releases to bar False Claims Act qui tam actions by former employees. In their article “Employee Releases: A Tool Federal Contractors Can Use To Protect Themselves Against False Claims Act Liability” published in the February 21, 2006, BNA Federal Contracts Report (http://www.crowell.com/pdf/newsroom/FCR_Kunz-Goodman.pdf), Cathy Kunz and Jody Goodman of C&M discuss the jurisprudence that releases cannot be used to prevent former employees from bringing FCA actions against employers and analyze two recent decisions that diverge from this precedent and open the door for the enforcement of employee releases to bar qui tam actions.
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
